| Fei Xu,Xiaoli Ren,Yuan Chen,Qianxia Li,Ruichao Li,Yu Chen,Shu Xia. Progress in the diagnosis and treatment of extensive-stage small cell lung cancer. Oncol Transl Med, 2019, 5: 33-42. |
| 广泛期小细胞肺癌的诊疗进展 |
| Progress in the diagnosis and treatment of extensive-stage small cell lung cancer |
| Received:December 11, 2018 Revised:March 03, 2019 |
| DOI：10.1007/s10330-018-0324-4 |
| 中文关键词: 小细胞肺癌,广泛期,靶向治疗,免疫治疗。 |
| 英文关键词: small cell lung cancer (SCLC); extensive-stage; targeted therapy; immunotherapy |
| 基金项目: |
| Author Name | Affiliation | E-mail | | Fei Xu | Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People’s Republic of China | 15172501812@163.com | | Xiaoli Ren | Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People’s Republic of China | | | Yuan Chen | Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People’s Republic of China | | | Qianxia Li | Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People’s Republic of China | | | Ruichao Li | Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People’s Republic of China | | | Yu Chen | Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People’s Republic of China | | | Shu Xia* | Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, People’s Republic of China | xiashutj@hotmail.com |
|
| Hits: 8393 |
| Download times: 11166 |
| 中文摘要: |
| 肺癌占全球每年新发恶性肿瘤病例的13%,是最常见的肿瘤类型。小细胞肺癌(small cell lung cancer, SCLC)约占每年新诊断肺癌病例的15%左右,其每年死亡人数占因肺癌死亡人数的25%。根据美国退伍军人协会专家小组对小细胞肺癌的分期,广泛期小细胞肺癌定义为病变范围超过半侧胸腔,包括恶性胸腔积液、恶性心包积液或已发生血行转移,而大约三分之二的小细胞肺癌患者在初诊时已为广泛期病变。在过去的二十年,基于临床试验的研究,依托泊苷联合铂类的化疗方案逐渐取代了环磷酰胺、阿霉素与长春新碱的联合方案(CAV),因此依托泊苷联合铂类药物(EP)作为一线方案广泛应用于广泛期小细胞肺癌患者的治疗,该方案使得广泛期病变患者中位生存期在8-13个月,5年生存率为1%-2%。本文从小细胞肺癌的流行病学、病理性及临床特点讲到广泛期小细胞肺癌的系统治疗,继而介绍目前涉及到的小细胞肺癌的靶向治疗与免疫治疗,为临床医生及患者提供更为系统、更为全面、临床获益更高的治疗方案。 |
| 英文摘要: |
| Lung cancer, being the most common cancer type, accounts for 13% of all newly diagnosed malignant
tumors globally each year. Small cell lung cancer (SCLC) accounts for approximately 15% of newly
diagnosed lung cancers each year, but its annual death toll accounts for 25% of that of lung cancer. We
summarized relevant clinical studies to elaborate the epidemiology, pathological and clinical characteristics
and the treatment status of small cell lung cancer. This paper first described the epidemiology and the
pathological and clinical characteristics of SCLC and the systematic treatment of extensive-stage SCLC
and then introduced the current targeted therapy and immunotherapy for SCLC to provide clinicians and
patients with a more systematic, comprehensive, and beneficial treatment regimen. We expect that these
studies can provide clinicians with a clear direction in molecularly targeted therapy or immunotherapy, so
that a treatment approach with better antitumor effects and longer-lasting clinical benefits can be provided
to the patients. |
|
View Full Text
Download reader HTML全文 |
| Close |
|
|
|